MedTrace Logo

Bipolar RFA Versus Phenol Neurolysis for Knee Osteoarthritis Pain

NCT07805161 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-09-04

No results posted yet for this study

Summary

This prospective observational comparative study evaluates the analgesic efficacy and safety of ultrasound-guided bipolar radiofrequency ablation (BPRFA) versus phenol chemical neurolysis (PCN) of the genicular nerves in patients with chronic knee osteoarthritis (gonarthrosis) refractory to conservative treatment.

Patients with moderate-to-severe chronic knee pain who demonstrate significant pain relief following diagnostic genicular nerve block undergo either BPRFA or PCN targeting the superior medial, superior lateral, and inferior medial genicular nerves under ultrasound guidance. Pain intensity and functional outcomes are assessed using the Numeric Rating Scale (NRS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline and during follow-up evaluations at 4, 12, and 24 weeks after treatment.

The study aims to compare pain reduction, functional improvement, responder rates, and procedure-related adverse events between the two treatment modalities.

Conditions

  • Gonarthrosis

Interventions

PROCEDURE

Phenol Chemical Neurolysis

Ultrasound-guided phenol neurolysis was performed targeting the superior medial, superior lateral, and inferior medial genicular nerves. Following confirmation of needle placement, 2 mL of 8% phenol was injected around each targeted genicular nerve.

PROCEDURE

Ultrasound-Guided Bipolar Radiofrequency Ablation

Ultrasound-guided bipolar radiofrequency ablation was performed using two parallel radiofrequency cannulas placed within 1 cm of each other targeting the superior medial, superior lateral, and inferior medial genicular nerves. Radiofrequency ablation was applied at 80°C for 90 seconds following sensory and motor stimulation testing.

Sponsors & Collaborators

  • Saglik Bilimleri Universitesi

    lead OTHER

Principal Investigators

  • Alp Eren Celenlioglu, MD./Assoc. Prof. · Department of Algology, University of Health Sciences Gulhane Training and Research Hospital, Ankara, Turkiye

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2025-06-01
Completion
2025-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07805161 on ClinicalTrials.gov